




RealRate

PHARMACEUTICAL 2019

VYNE Therapeutics Inc.
Rank 142 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

**RealRate**

PHARMACEUTICAL 2019

VYNE Therapeutics Inc.
Rank 142 of 371



The relative strengths and weaknesses of VYNE Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VYNE Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 244% points. The greatest weakness of VYNE Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 137% points.

The company's Economic Capital Ratio, given in the ranking table, is -88%, being 244% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	139,500
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,544
Liabilities, Non-Current	7.0
Other Assets	282
Other Compr. Net Income	-45
Other Expenses	0
Other Liabilities	0
Other Net Income	3,090
Property and Equipment	146
Research and Development	52,989
Revenues	10,640
Selling, General and Administrative Expense	12,186

Output Variable	Value in 1000 USD
Assets	139,928
Liabilities	9,551
Expenses	65,175
Stockholders Equity	130,377
Net Income	-51,445
Comprehensive Net Income	-51,468
Economic Capital Ratio	-88%

**RealRate**

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai